Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,otherAssets,netReceivables,otherStockholderEquity,shortTermInvestments,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,issuanceOfStock,investments,totalCashflowsFromInvestingActivities,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,gmtOffSetMilliseconds,esgPopulated,tradeable,market,exchange,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,priceHint,marketState,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,ELOX,2750000.0,86189600,4073000,,-8694000,,-8694000,4341000,0,-8414000,-8414000,,-260000,,,,0,0,8414000,0,-280000,,-8694000,-8694000,184558000.0,17616000.0,2750000.0,38000.0,20366000.0,404000.0,1416000.0,-180290000.0,-1922000.0,18247000.0,12693000.0,5562000.0,406000.0,19960000.0,4913000.0,485000.0,,,,,4000.0,-1250000.0,1262000.0,-561000.0,-6423000.0,-94000.0,-7685000.0,148000.0,2606000.0,1308000.0,,,,,7267000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-2.4691334,1.57 - 1.65,1.62,1.57,1.58,12,12,finmb_251924233,NasdaqGM,"Eloxx Pharmaceuticals, Inc.",USD,1552965,497783,-14400000,False,False,us_market,NGM,-0.73,-0.55,-1.03,-1.5339806,0.068,1.4177778,0.16222227,0.11442009,2.2939856,-0.71398556,-0.3112424,136179568,-2.8727274,23.235294,15,America/New_York,EDT,1.58,1630508410,-0.03999996,1.61,1.65,1.57,157792,"Eloxx Pharmaceuticals, Inc.",4,REGULAR,0,0.4000001,0.33898315,1.18 - 6.77,-5.19,-0.7666174,1.18,6.77,1513728000,1620390600,1628080200,1628512200,2.28,,,6.77,1.18,1.4178,2.294,1.55M,497.78k,86.19M,,31.95M,9.37%,34.36%,1.91M,1.73,2.61%,2.22%,1.67M,,,,,,0.00%,"Dec 19, 2017",,1:20,"Dec 19, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-52.07%,-202.19%,,,,,-28.01M,-29.32M,-0.7300,,18.25M,0.38,14.18M,515.49,1.57,0.07,-23.93M,-13.34M,Value,02451,Healthcare,25,9,7,"Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.",Waltham,781 577 5300,MA,1,1609372800,1625097600,5,United States,http://www.eloxxpharma.com,86400,4,950 Winter Street,Biotechnology
t-1,ELOX,10230000.0,86189600,2682000,,-6127000,,-6127000,3100000,0,-5782000,-5782000,,-319000,,,,0,0,5782000,0,-345000,,-6127000,-6127000,183250000.0,16247000.0,10230000.0,296000.0,26477000.0,404000.0,1055000.0,-171596000.0,-1828000.0,24668000.0,9838000.0,5239000.0,554000.0,25893000.0,6376000.0,481000.0,30000.0,,,,-157000.0,-1250000.0,-1252000.0,64000.0,-5920000.0,-3000.0,-4668000.0,146000.0,2606000.0,1281000.0,1000.0,,,,16055000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-2.4691334,1.57 - 1.65,1.62,1.57,1.58,12,12,finmb_251924233,NasdaqGM,"Eloxx Pharmaceuticals, Inc.",USD,1552965,497783,-14400000,False,False,us_market,NGM,-0.73,-0.55,-1.03,-1.5339806,0.068,1.4177778,0.16222227,0.11442009,2.2939856,-0.71398556,-0.3112424,136179568,-2.8727274,23.235294,15,America/New_York,EDT,1.58,1630508410,-0.03999996,1.61,1.65,1.57,157792,"Eloxx Pharmaceuticals, Inc.",4,REGULAR,0,0.4000001,0.33898315,1.18 - 6.77,-5.19,-0.7666174,1.18,6.77,1513728000,1620390600,1628080200,1628512200,2.28,,,6.77,1.18,1.4178,2.294,1.55M,497.78k,86.19M,,31.95M,9.37%,34.36%,1.91M,1.73,2.61%,2.22%,1.67M,,,,,,0.00%,"Dec 19, 2017",,1:20,"Dec 19, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-52.07%,-202.19%,,,,,-28.01M,-29.32M,-0.7300,,18.25M,0.38,14.18M,515.49,1.57,0.07,-23.93M,-13.34M,Value,02451,Healthcare,25,9,7,"Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.",Waltham,781 577 5300,MA,1,1609372800,1625097600,5,United States,http://www.eloxxpharma.com,86400,4,950 Winter Street,Biotechnology
t-2,ELOX,15078000.0,86189600,3231000,,-6617000,,-6617000,3065000,0,-6296000,-6296000,,-327000,,,,0,0,6296000,0,-321000,,-6617000,-6617000,181969000.0,17864000.0,15078000.0,1420000.0,32942000.0,403000.0,1329000.0,-165469000.0,-1825000.0,30592000.0,9985000.0,4917000.0,700000.0,32212000.0,7823000.0,638000.0,30000.0,35000.0,,,-132000.0,-1250000.0,-1247000.0,-209000.0,245000.0,-3000.0,-5258000.0,143000.0,2606000.0,1420000.0,6000.0,6750000.0,6750000.0,,22227000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-2.4691334,1.57 - 1.65,1.62,1.57,1.58,12,12,finmb_251924233,NasdaqGM,"Eloxx Pharmaceuticals, Inc.",USD,1552965,497783,-14400000,False,False,us_market,NGM,-0.73,-0.55,-1.03,-1.5339806,0.068,1.4177778,0.16222227,0.11442009,2.2939856,-0.71398556,-0.3112424,136179568,-2.8727274,23.235294,15,America/New_York,EDT,1.58,1630508410,-0.03999996,1.61,1.65,1.57,157792,"Eloxx Pharmaceuticals, Inc.",4,REGULAR,0,0.4000001,0.33898315,1.18 - 6.77,-5.19,-0.7666174,1.18,6.77,1513728000,1620390600,1628080200,1628512200,2.28,,,6.77,1.18,1.4178,2.294,1.55M,497.78k,86.19M,,31.95M,9.37%,34.36%,1.91M,1.73,2.61%,2.22%,1.67M,,,,,,0.00%,"Dec 19, 2017",,1:20,"Dec 19, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-52.07%,-202.19%,,,,,-28.01M,-29.32M,-0.7300,,18.25M,0.38,14.18M,515.49,1.57,0.07,-23.93M,-13.34M,Value,02451,Healthcare,25,9,7,"Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.",Waltham,781 577 5300,MA,1,1609372800,1625097600,5,United States,http://www.eloxxpharma.com,86400,4,950 Winter Street,Biotechnology
t-3,ELOX,20291000.0,86189600,3528000,,-7887000,,-7887000,4058000,0,-7586000,-7586000,,-347000,,,,0,0,7586000,0,-301000,,-7887000,-7887000,180549000.0,19630000.0,20291000.0,1801000.0,39921000.0,403000.0,1622000.0,-158852000.0,-1809000.0,30347000.0,10771000.0,5149000.0,843000.0,38968000.0,8704000.0,770000.0,110000.0,1000.0,13000.0,6769000.0,-619000.0,-453000.0,-456000.0,-102000.0,4481000.0,-3000.0,-6316000.0,161000.0,2606000.0,1987000.0,6000.0,11250000.0,11253000.0,3000.0,28197000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-2.4691334,1.57 - 1.65,1.62,1.57,1.58,12,12,finmb_251924233,NasdaqGM,"Eloxx Pharmaceuticals, Inc.",USD,1552965,497783,-14400000,False,False,us_market,NGM,-0.73,-0.55,-1.03,-1.5339806,0.068,1.4177778,0.16222227,0.11442009,2.2939856,-0.71398556,-0.3112424,136179568,-2.8727274,23.235294,15,America/New_York,EDT,1.58,1630508410,-0.03999996,1.61,1.65,1.57,157792,"Eloxx Pharmaceuticals, Inc.",4,REGULAR,0,0.4000001,0.33898315,1.18 - 6.77,-5.19,-0.7666174,1.18,6.77,1513728000,1620390600,1628080200,1628512200,2.28,,,6.77,1.18,1.4178,2.294,1.55M,497.78k,86.19M,,31.95M,9.37%,34.36%,1.91M,1.73,2.61%,2.22%,1.67M,,,,,,0.00%,"Dec 19, 2017",,1:20,"Dec 19, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-52.07%,-202.19%,,,,,-28.01M,-29.32M,-0.7300,,18.25M,0.38,14.18M,515.49,1.57,0.07,-23.93M,-13.34M,Value,02451,Healthcare,25,9,7,"Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.",Waltham,781 577 5300,MA,1,1609372800,1625097600,5,United States,http://www.eloxxpharma.com,86400,4,950 Winter Street,Biotechnology
